Lactose India Ltd. Posts Robust Q1 FY27 Financials Amidst Warrant Forfeiture

Revenue from Operations: ₹46.97 crore | Net Profit After Tax: ₹2.37 crore

Reader Takeaway: Strong profit growth but a key capital raise failed; merger progress is key.

What just happened

Lactose (India) Limited reported its unaudited financial results for the quarter ending June 30, 2026. The company posted a 18.6% year-on-year increase in revenue from operations, reaching ₹46.97 crore, and a significant 57.8% rise in net profit after tax to ₹2.37 crore. Basic Earnings Per Share (EPS) grew to ₹1.88 from ₹1.19.

However, the company also announced the forfeiture of 15,00,000 convertible share warrants from a previous preferential issue. These warrants were not exercised by the holders who failed to remit the remaining 75% subscription amount. The upfront 25% payment of ₹6.53 crore has been forfeited and transferred to the company's Capital Reserve.

Furthermore, the proposed merger with Vitanosh Ingredients Private Limited is still pending final approvals from SEBI and the National Company Law Tribunal (NCLT). These financials do not include any impact from the merger.

Why this matters

The strong financial performance demonstrates Lactose India's operational growth and improved profitability. The warrant forfeiture, while boosting capital reserves by ₹6.53 crore, signifies a failure to secure the full expected capital from that specific issuance, potentially impacting future expansion plans. The pending merger is a crucial development that could reshape the company's structure and operations.

The backstory

Lactose India operates in the 'Pharmaceuticals' segment. The company had previously announced a preferential issue involving convertible warrants. The merger with Vitanosh Ingredients Private Limited has been a subject of discussion, with shareholder approval already obtained, but regulatory hurdles remain.

What changes now

The forfeited amount has been booked as a one-time boost to the company's Capital Reserve. Investors will need to reassess the company's capital-raising strategy going forward. The merger's progress will be a key factor influencing the company's future trajectory.

Risks to watch

The primary risk lies in the failed capital infusion from the warrant holders, which could hinder planned growth initiatives. Additionally, the uncertain timeline for regulatory approvals for the Vitanosh Ingredients merger poses a risk to its completion.

Peer comparison

As a pure-play pharmaceutical entity, Lactose India's performance will be benchmarked against other pharmaceutical companies. While specific peer financial data for Q1 FY27 is not provided, general industry trends in revenue growth and profitability will be relevant for comparison.

Context metrics (time-bound)

• Revenue Growth: Increased by 18.6% year-on-year for the quarter ended 30th June 2026.
• Net Profit Growth: Increased by 57.8% year-on-year for the quarter ended 30th June 2026.
• Warrant Forfeiture: ₹6.53 crore forfeited during the quarter ended 30th June 2026.

What to track next

Investors should closely track the progress of the Vitanosh Ingredients merger and any updates from SEBI and NCLT. Furthermore, management's plans for future capital raising and growth strategies will be important to monitor.